Related Experiment Video
Updated: Apr 1, 2026
10:16
Generating Genetically Modified Plasmodium berghei Sporozoites
Published on: May 5, 2023
1.8K
Recent advances in recombinant protein-based malaria vaccines
Simon J Draper1, Evelina Angov2, Toshihiro Horii3
1The Jenner Institute, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK.
Vaccine
|October 14, 2015
Summary
Developing effective malaria vaccines is crucial. This review highlights recent advances in protein-based vaccine design and clinical testing for various Plasmodium parasite stages, aiming for a comprehensive malaria vaccine.
Area of Science:
- Immunology
- Vaccinology
- Parasitology
Background:
- Malaria, caused by Plasmodium parasites, necessitates a highly effective vaccine targeting infection, disease, and transmission.
- Antibodies induced by vaccines can target multiple parasite lifecycle stages in humans and mosquitoes.
- Protein subunit vaccination, using antigens with adjuvants, is a primary strategy for antibody induction.
Purpose of the Study:
- To review recent progress in protein vaccine design, development, and clinical testing for malaria.
- To discuss leading malaria antigens across different parasite lifecycle stages.
- To explore future prospects and challenges in protein-based malaria vaccine development.
Main Methods:
- Review of recent literature on malaria vaccine development.
- Focus on protein antigen discovery, expression platforms, and delivery systems (e.g., VLPs).
- Analysis of clinical trial data and preclinical studies for key malaria antigens.
Main Results:
- Significant advancements in protein vaccine design and delivery platforms.
- Exploration of next-generation subunit designs for improved efficacy.
- Progress in clinical testing of vaccines targeting sporozoite, merozoite, and sexual stages.
Conclusions:
- Protein-based vaccines offer a promising avenue for a multi-component malaria vaccine.
- Continued innovation in antigen selection, formulation, and delivery is essential.
- Addressing challenges in production, human delivery, and assessment is critical for future vaccine success.
